Parecoxib: Parenteral selective COX 2 inhibitor (coxib) for postoperative pain management

Parecoxib (brand name Dynastat, Pfizer) is the only parenteral selective cyclooxygenase 2 inhibitor (coxib) and was approved in Europe in 2002 for short term treatment of postoperative pain. It is a water soluble prodrug of valdecoxib that is rapidly hydrolyzed to the active form following intravenous or intramuscular administration.

Parecoxib has become an established valuable tool in perioperative pain management because it combines the strong analgesic effect of NSAIDs with reduced gastrointestinal irritation and without affecting platelet aggregation. This property makes it particularly suitable for patients with increased GI bleeding risk or during operations where unimpaired hemostasis is important (however, use in cardiac surgery after CABG is contraindicated).

Mechanism of action

Parecoxib is rapidly hydrolyzed in plasma by esterases to valdecoxib (hydrolysis half life less than 30 minutes). Valdecoxib is a selective inhibitor of cyclooxygenase 2 (COX 2) with approximately 20,000 fold selectivity over COX 1.

COX 2 is an inducible enzyme that is mainly upregulated in inflammation, pain, and fever, while COX 1 is constitutively expressed in the stomach, kidneys, and platelets and has protective and homeostatic functions. Selective COX 2 inhibition therefore reduces inflammation and pain without impairing stomach protective prostaglandin synthesis (via COX 1). The result is fewer gastrointestinal ulcers and bleeding than with conventional NSAIDs.

Unlike non selective NSAIDs, parecoxib does not inhibit platelet COX 1, so platelet aggregation and bleeding time remain unaffected. This property allows use in the perioperative phase without increased bleeding risk from a surgical perspective.

Indications

• Short term postoperative pain management: following orthopedic, abdominal, and gynecological procedures
• Multimodal analgesia: in combination with opioids, local anesthetics, and paracetamol to reduce opioid requirements
• In patients with increased GI bleeding risk: as an alternative to conventional NSAIDs
• Off label: acute migraine, kidney stone colic (rarely used due to parenteral administration)

Parecoxib is not approved for postoperative pain management after coronary artery bypass grafting (CABG) because studies showed increased risk of cardiovascular complications in this setting.

Dosage and administration

Adults: 40 mg intravenously or intramuscularly as initial dose, then 20 or 40 mg every 6 to 12 hours as needed, maximum daily dose 80 mg. Duration of use should be kept as short as possible, generally not longer than 3 days.

Elderly patients aged 65 years and older with body weight below 50 kg: Initial dose 20 mg, subsequent doses 20 mg.

In moderate hepatic insufficiency (Child Pugh 7 to 9): Initial dose 20 mg, maximum daily dose 40 mg. In severe hepatic insufficiency: contraindicated.

In renal insufficiency: exercise caution and close creatinine monitoring in moderate to severe functional impairment.

Adverse effects

Common: nausea, vomiting, abdominal pain, hypertension, hypotension, edema, postoperative anemia, pruritus, rash.

Serious: cardiovascular events (myocardial infarction, stroke, thromboembolism), particularly in patients with cardiovascular risk factors or after coronary artery bypass grafting; acute renal failure; gastrointestinal ulcers and bleeding (lower than with conventional NSAIDs, but not zero); severe skin reactions such as Stevens Johnson syndrome, toxic epidermal necrolysis (TEN), erythema multiforme; allergic reactions including anaphylaxis; bronchospasm in NSAID allergy.

Important: the severe skin reactions led to worldwide market withdrawal of valdecoxib (Bextra) as an oral substance in 2005, but parecoxib remains approved for short term parenteral use with appropriate safety monitoring.

Drug interactions

• Other NSAIDs: additive gastrointestinal and renal risks, avoid combination
• Anticoagulants (warfarin, NOACs, heparin): increased bleeding risk, INR monitoring
• ACE inhibitors and sartans: reduced efficacy, additive renal insufficiency
• Diuretics: reduced efficacy
• Lithium: elevated lithium levels
• Methotrexate: elevated MTX levels and toxicity, especially with high dose MTX
• Fluconazole: elevated parecoxib/valdecoxib levels due to CYP2C9 inhibition

Special notes

Pregnancy and lactation: contraindicated especially in the third trimester due to risk of premature closure of the ductus arteriosus Botalli and neonatal renal effects. Not recommended during breastfeeding.

Contraindications: active peptic ulcer or bleeding; inflammatory bowel disease; severe heart failure; known ischemic heart disease, peripheral arterial occlusive disease, stroke in medical history (relative contraindication, individual risk benefit assessment); after coronary artery bypass grafting absolute contraindication; known sulfonamide allergy; pregnancy third trimester; severe hepatic insufficiency; eGFR below 30 ml/min.

Shortest treatment duration: Parecoxib should be used as briefly as possible, generally not longer than 3 days. Conversion to oral analgesics (ibuprofen, paracetamol, metamizole) is done early.

Skin reactions: if rash, mucosal lesions, or other allergic reactions occur, discontinue therapy immediately.

You may also be interested in

• Celecoxib, orally available coxib
• Etoricoxib, another oral coxib
• Ibuprofen, conventional NSAID
• Paracetamol, standard analgesic
• Metamizole, pyrazolone analgesic with spasmolytic effect

Frequently asked questions

Sources

• EMA, Dynastat (Parecoxib) EPAR
• DGAI recommendations for postoperative pain management
• Gelbe Liste, Parecoxib active ingredient profile
• BfArM, Federal Institute for Drugs and Medical Devices